Literature DB >> 12515392

Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death.

Young Do Yo1, Young Min Chung, Jong Kuk Park, Chul Min Ahn, Sung Kyu Kim, Hyung Jung Kim.   

Abstract

Peroxiredoxin II (Prx II) is known not only to protect cells from oxidative damage caused by hydrogen peroxide (H202), but also to endow cancer cells with resistance to both H202 and cisplatin and to grant them radioresistance. In this study, we examined whether Prx II antisense could enhance cisplatin-induced cell death. When gastric cancer cells were transfected with various concentrations of Prx II antisense plasmid, pPrxII/AS, and then treated with the same concentrations of cisplatin, Prx II antisense enhanced cisplatin-induced cell death. The combination index (CI) at all doses of the combination was below 1, indicating that Prx II antisense sensitized cisplatin-induced cell death. This synergism was also observed in the cells transfected with a Prx II antisense oligomer. Our present results, therefore, suggest that Prx II antisense would be a very good sensitizer for cisplatin, and that Prx II as a target for chemosensitizers constitutes a promising avenue for future research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12515392     DOI: 10.1038/emm.2002.38

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  13 in total

1.  Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.

Authors:  Francesca Magherini; Alessandra Modesti; Luca Bini; Michele Puglia; Ida Landini; Stefania Nobili; Enrico Mini; Maria Agostina Cinellu; Chiara Gabbiani; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2010-01-29       Impact factor: 3.358

2.  Whole-genome sequencing of Tarim red deer (Cervus elaphus yarkandensis) reveals demographic history and adaptations to an arid-desert environment.

Authors:  Buweihailiqiemu Ababaikeri; Shamshidin Abduriyim; Yilamujiang Tohetahong; Tayerjan Mamat; Adil Ahmat; Mahmut Halik
Journal:  Front Zool       Date:  2020-10-16       Impact factor: 3.172

3.  Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer.

Authors:  Jung Mi Byun; Su Sun Kim; Ki Tae Kim; Mi Seon Kang; Dae Hoon Jeong; Dae Sim Lee; Eun Jung Jung; Young Nam Kim; Jin Han; In Sung Song; Kyoun Bok Lee; Moon Su Sung
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

4.  Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells' survival by protecting cells from oxidative stress.

Authors:  Weidong Lu; Zhongxue Fu; Hao Wang; Jihong Feng; Jinlai Wei; Jinbao Guo
Journal:  Mol Cell Biochem       Date:  2013-11-15       Impact factor: 3.396

Review 5.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

6.  Comparative proteomics analysis of human gastric cancer.

Authors:  Wei Li; Jian-Fang Li; Ying Qu; Xue-Hua Chen; Jian-Min Qin; Qin-Long Gu; Min Yan; Zheng-Gang Zhu; Bing-Ya Liu
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

Review 7.  Mitochondrial peroxiredoxin III is a potential target for cancer therapy.

Authors:  In-Sung Song; Hyoung-Kyu Kim; Seung-Hun Jeong; Sung-Ryul Lee; Nari Kim; Byoung Doo Rhee; Kyung Soo Ko; Jin Han
Journal:  Int J Mol Sci       Date:  2011-10-21       Impact factor: 5.923

8.  Peroxiredoxin 2 is associated with colorectal cancer progression and poor survival of patients.

Authors:  LingLong Peng; Rong Wang; JingKun Shang; YongFu Xiong; ZhongXue Fu
Journal:  Oncotarget       Date:  2017-02-28

Review 9.  Peroxiredoxin II Regulates Cancer Stem Cells and Stemness-Associated Properties of Cancers.

Authors:  Nisansala Chandimali; Dong Kee Jeong; Taeho Kwon
Journal:  Cancers (Basel)       Date:  2018-09-03       Impact factor: 6.639

10.  Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus.

Authors:  Eui Joo Kim; Yoon Jae Kim; Hye In Lee; Seok-Hoo Jeong; Hyo Jung Nam; Jae Hee Cho
Journal:  Antioxidants (Basel)       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.